A Review on Finasteride: A 5-Alpha Reductase Inhibitors, its Mechanism, Facts and Benefits
This review gives the information about the Finasteride i.e. 5alpha-reductase inhibitor. Primarily finasteride isused to treat BPH i.e benign prostatic hyperplasia and male androgenetic alopecia. Five-alpha reductase inhibitors (5α-RIs) could stimulate male sexual dysfunction due to their effects on testosterone and DHT i.e. dihydrotestosterone. Some studies account insignificant or acceptable adverse effects, which decrease after a changeable period of time so that they do not require terminating finasteride administration. The 5alpha-reductase inhibitor finasteride blocks the conversion of TT to DHT i.e. testosterone to dihydrotestosterone (DHT), the androgen responsible for androgenetic alopecia i.e. male pattern hair loss. This paper presents a possible explanation of the Finasteride drug.
Keywords: Finasteride, 5alpha-reductase inhibitor, BPH, DHT, alopecia.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).